BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson Sells 68,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 68,000 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $2,467,720.00. Following the transaction, the chief financial officer now owns 93,758 shares of the company’s stock, valued at $3,402,477.82. The trade was a 42.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

BridgeBio Pharma Stock Down 1.3 %

BBIO stock traded down $0.49 during trading on Thursday, hitting $35.97. 2,154,592 shares of the company’s stock traded hands, compared to its average volume of 2,899,899. The firm has a market capitalization of $6.80 billion, a P/E ratio of -14.93 and a beta of 1.05. The business has a fifty day simple moving average of $29.64 and a two-hundred day simple moving average of $27.10. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $41.04.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BBIO. Allspring Global Investments Holdings LLC lifted its position in BridgeBio Pharma by 17.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after buying an additional 801 shares in the last quarter. Amalgamated Bank increased its position in shares of BridgeBio Pharma by 24.7% in the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock valued at $123,000 after purchasing an additional 962 shares during the last quarter. Diversified Trust Co raised its holdings in BridgeBio Pharma by 3.0% during the third quarter. Diversified Trust Co now owns 36,772 shares of the company’s stock worth $936,000 after purchasing an additional 1,059 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BridgeBio Pharma by 21.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock valued at $170,000 after purchasing an additional 1,214 shares during the period. Finally, Advisors Asset Management Inc. increased its stake in BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after purchasing an additional 1,645 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on BBIO. Evercore ISI raised their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Bank of America raised their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Scotiabank upped their price objective on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, November 25th. Leerink Partners reduced their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research note on Monday, December 16th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus target price of $48.08.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.